Novanta Acquires Riverpoint Medical for $1.2 Billion

Novanta has agreed to acquire Riverpoint Medical from Arlington Capital Partners in a transaction valued at up to $1.45 billion. The deal, involving an upfront cash payment of $1.2 billion with a contingent $250 million milestone payment scheduled for 2027, aims to enhance Novanta's footprint in the minimally invasive surgical consumable market. Scheduled to close in the third quarter of 2026, the acquisition awaits standard regulatory clearances and closing conditions.

Riverpoint Medical, based in Portland, Oregon, specializes in the development and manufacturing of private-label surgical consumables and instruments, predominantly used in sports medicine, trauma, and cardiovascular procedures. The company's offerings include sutures and implantable materials, featuring proprietary coating technologies. Novanta expects the acquisition to significantly boost its recurring revenue, doubling it to approximately $300 million while elevating its medical market exposure to about 60% of total revenue.

For Novanta, the acquisition is a strategic move to accelerate growth and enhance product offerings. The company projects that Riverpoint will deliver an annual revenue growth rate of 12% to 15%, considerably faster than Novanta's existing operations. Additionally, the acquisition is anticipated to provide access to a $2 billion addressable market, with synergistic opportunities expected to generate around $80 million in adjusted EBITDA by 2027, including synergies.

In the broader medical devices sector, this acquisition positions Novanta to benefit from an expanded manufacturing presence, with facilities in both Portland, Oregon, and San Jose, Costa Rica. This enhanced footprint is likely to improve supply chain resilience and operational responsiveness, crucial in the highly regulated medical devices market. The integration of Riverpoint’s capabilities is aligned with Novanta’s strategy to serve medical original equipment manufacturers more effectively.

Financing for the deal will leverage cash on hand, an existing credit facility, and proceeds from a recent $300 million equity offering. Novanta anticipates the acquisition will immediately contribute to adjusted diluted earnings per share by 2026, with positive impacts on revenue growth, margins, and operating cash flows emerging in 2027. As regulatory approvals and integration proceed, market participants will closely monitor Novanta's execution of its expanded strategy.